News | November 21, 2017

Arvinas and Macroceutics Establish DEL Screening Collaboration on Undruggable Targets NEW HAVEN, Conn. and Monmouth Junction New Jersey, November 21, 2017 – Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, and...

News | December 13, 2017

Principia Biopharma initiates clinical trial for PRN1008 in patients with Immune Thrombocytopenia Purpura Preclinical Data Presented at American Society of Hematology Annual Meeting Support ITP Indication  SOUTH SAN FRANCISCO, CALIF., December 13, 2017  Principia...

News | December 7, 2017

CRISPR Therapeutics Submits First Clinical Trial Application for a CRISPR Gene-Edited Therapy, CTX001 in β-thalassemia -Phase 1/2 trial in β-thalassemia expected to begin in 2018- ZUG, Switzerland and CAMBRIDGE, Mass., Dec. 07, 2017 (GLOBE NEWSWIRE) — CRISPR...
libero. ante. risus. ut Praesent Nullam sed velit, sit efficitur. commodo luctus